Our Stocks to Watch today include Access Pharmaceuticals Inc. (OTCBB: ACCP), China Youth Media Inc. (OTCBB: CHYU), eWorld Companies Inc. (OTC: EWRC), Kender Energy Inc. (OTC: KNDR), Organa Gardens International Inc. (OTCBB: OGNG), Jaguar Mining Enterprises Inc. (OTC: JAGR), Fountain Healthy Aging Inc. (OTCBB: FHAI), BioElectronics Corp. (OTC: BIEL), VerifySmart Corp. (VSMR: OTCBB), Discovery Laboratories Inc. (Nasdaq: DSCO), Speedus Corp. (Nasdaq: SPDE) and VIA Pharmaceuticals Inc. (Nasdaq: VIAP).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
ACCESS PHARMACEUTICALS INCORPORATED (OTCBB: ACCP)
"Up 3.12% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ACCP.php
Company Profile: http://www.otcpicks.com/access-pharmaceuticals/access-pharmaceuticals.htm
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
ACCP News:
September 11 - Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the
Access Pharmaceuticals Inc. (OTCBB: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more
In a comparison of cancer patients receiving standard oral mucositis care with those patients receiving MuGard , MuGard has been shown to significantly reduce the incidence and severity of the debilitating side effect of radiation treatment and chemotherapy.
Access has contracted with Accupac, Inc. to serve as its commercial manufacturer of MuGard in
"Access is moving forward with the development of MuGard in
Access intends to use the initial batches of MuGard in connection with one or more market seeding studies to be conducted in the
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop symptoms. MuGard is currently being marketed in the
Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide.
Detailed Quote: http://www.otcpicks.com/quotes/CHYU.php
Company Profile: http://www.otcpicks.com/china-youth-media/china-youth-media.htm
China Youth Media, Inc. is a China-focused youth marketing and media company whose business is to deliver advertising and content to one of the most sought after and fastest growing demographics in the world. Through its wholly owned subsidiary Youth Media (Hong Kong) Limited, CHYU has secured contracts with a term of 20 plus 10 years that provide exclusive rights from the Chinese government controlled corporation, China Youth Interactive, which uniquely position CHYU to market to China’s massive student population with preferred access online, on campus and on mobile. CHYU currently targets
CHYU News:
September 9 -
China Youth Media, Inc. (OTCBB: CHYU), a China focused youth marketing and media company, announced that its Koobee Network has launched an advertising campaign for the athletic footwear company Converse, a subsidiary of the world’s leading athletic shoes and apparel company, Nike.
Koobee, China Youth Media’s Intranet Television Network and media portal, delivers TV-quality content and advertising directly to China’s 30 million plus college students on a dedicated network targeted to campuses nationwide. The Converse ad campaign is running on Koobee’s recently launched MOGO Music Channel. Produced for and targeted specifically to
“We are very pleased to launch the Converse campaign on Koobee and expect it to become one of many to generate ad revenue for the company,” commented Jay Rifkin, China Youth Media’s CEO. “As more campaigns like this are sold, we believe that Koobee’s highly targeted youth platform will become premium ad inventory for major global brands.”
EWORLD COMPANIES INCORPORATED (OTC: EWRC)
"Up 7.14% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EWRC.php
Company Profile: http://www.otcpicks.com/eworld-companies/eworld-companies.htm
eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise online. eWorld's revenue model consists of seven components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3) Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising Revenues, (6) Web Development Accounts, and (7) International Licensing Fees.
EWRC News:
September 10 - eWorld Companies Board of Directors Approves Offer for Purchase of Outstanding Shares at 1.9 Cents
eWorld Companies, Inc. (OTC: EWRC) announced that its Board of Directors has approved an offer for purchase of all outstanding shares at 1.9 cents a share pending completion of due diligence and approval by their attorneys. Upon completion of this due diligence and approval, the company will make a recommendation to its shareholders.
eWorld Companies Presents 2nd Annual eWorld Music Awards
eWorld Companies, Inc. (OTC: EWRC) presents the 2nd Annual eWorld Music Awards (EMAs), the only event of its kind celebrating truly independent music, voted for by the fans.
In conjunction with this release, eWorld CEO Henning Morales stated that over the next few months the eWorld Music Awards and Show will become the company's primary focus, and are expected to play a significant role in the company's near-term goals of generating one to two million new Boomerang downloads and at least $1,000,000 monthly gross profits.
The EMA's will also introduce audiences and participants to an exciting new format geared to today's generation of artists and music lovers. Billed as the "World's Fastest Music Award Show - A One-Hour-Only Live Awards Jam," the action will be fast and furious, serving up a live musical performance of a premier Indie band plus 10 live performances by nominees, and delivering 13 separate awards, all in a one-hour broadcast. The live event, which will take place during Grammys week on January 29, 2010, will be broadcast worldwide via the Internet and possibly as a one-hour live television event as well.
The EMAs will be held at the famed Barker Hangar in
Music submissions are being accepted now at www.eworldmusicawards.com. Nominee selection will be made by a Blue Ribbon Panel of singers, songwriters, producers, and other music industry professionals based on originality and overall quality of each submission. In late November the Panel will begin selecting the top nominees in each category to advance to a final audience voting round. Audience voting will begin online on December 15, 2009, and will remain open up to five minutes before the announcement of each winner at the Awards show. Cash prizes will be awarded to the winners from each category.
KENDER ENERGY INCORPORATED (OTC: KNDR)
Detailed Quote: http://www.otcpicks.com/quotes/KNDR.php
Company Profile: http://www.otcpicks.com/kender-energy.htm
Kender Energy Inc. is a development phase company active in the field of solar energy. Its present prototypes of solar panels are being developed into a full-scale solar energy production system. The particularity of the Kender solar panel system and technology is to allow, via a closed circuit of gas (usually helium), to create a heat exchange with the sunlight and the air from the environment. The exchange generates the spinning of the helium gas in the closed circuit, propelling a turbine, which produces electricity in a 100% clean and renewable process. The system's main advantages are that it is efficient, cheap in production, and modular. The company is based near
KNDR News:
September 10 - Kender Energy to Distribute Its Solar Technology in
Kender Energy Inc. (OTC: KNDR) announced that it has signed a distribution agreement for the country of
"
September 9 - Kender Energy Publishes Its Corporate Video Profile
Kender Energy Inc. (OTC: KNDR) announced that it has published its corporate video profile on its website at www.kendersolar.com/index.php/Kender-Corporate-Video.html.
ORGANA GARDENS INTERNATIONAL INCORPORATED (OTCBB: OGNG)
Detailed Quote: http://www.otcpicks.com/quotes/OGNG.php
Company Profile: http://www.otcpicks.com/Newsletter/OGNA_NA_090909.html
Organa Gardens International Inc. has a vertical hydroponics farming system built to make the most efficient use of light, energy, water, land, temperature and production cycle while growing the highest quality and healthiest plants in an optimum, consistent environment unaffected by weather. The Organa Garden Systems (OGS) provide a means for food production and consumption change to global environmental and ecological sustainability through vertical hydroponics rotary farming.
OGNG News:
September 10 - Global Market Demand for Premium Organic Foods Continues
Organa Gardens International Inc. (OTCBB: OGNG) has a vertical hydroponic farming system known as OGS-E. The OGS-E will virtually eliminate current problems like transportation costs, pollution and product spoilage while enabling the grower/farmer to realize the same crop yield using between one-fifth to one-tenth the land currently needed depending on the crop being grown. The fully automated system recycles and reuses 95% of the water used while requiring a negligible amount of energy to run. The system uses a specially developed nutrient fertilizer which enables it to produce a higher quality of fruits and vegetables.
In a March 2009 report by Global Business Insights, "The organic food and drinks market grew rapidly over the first part of the decade with sales in the
More and more people are turning to organic food as a more reliable and safer way to feed themselves and their family. Artificial ingredients used to make a product low fat or low in calories are starting to be questioned. Strange-sounding ingredients are a concern for consumers. Most consumers now recognize the fact that non-organic foods can contain pesticides, chemical fertilizers and herbicides. Food scares such as BSE and more recently Avian Flu have not only had a detrimental effect on various industries, but also awakened consumer interest in where their food actually comes from. Consumers are starting to question the trust and loyalty they have placed in the food and drinks industry to date.
Organa is in the process of bringing its OGS-E into commercial production and feels its gardening technology is the answer for the concerned consumer. Company president Christopher Scheive states, "Organa's reinventing the food wheel will enable consumers to grow organic goods without the risks of pesticides, crop pests, and soil borne diseases while reaping the rewards of higher yields and seasonal extension of crop growth."
JAGUAR MINING ENTERPRISES INCORPORATED (OTC: JAGR)
Detailed Quote: www.otcpicks.com/quotes/JAGR.php
Company Profile: http://www.otcpicks.com/jaguar-mining/jaguar-mining.htm
Jaguar Mining Enterprises, Inc. is an independent mining company engaged in the acquisition, development, and exploitation of iron ore primarily mined in
JAGR News:
September 9 - Jaguar Mining Enterprises Issues Special Letter to Shareholders
Jaguar Mining Enterprises, Inc. (OTC: JAGR), an independent mining company engaged in the acquisition, development, and exploitation of iron ore primarily mined in Mexico, announced that it has issued a Special Letter to Shareholders to update existing JAGR investors on the current status of Jaguar Mining, and more importantly, its future growth outlook. Excerpts from the letter follow:
"Currently, our primary emphasis is to develop an iron ore reserve containing 20 million metric tons (mt) at our Cascaronal Project in
"In spite of recent market volatility, we expect that rising worldwide demand will likely produce a tight market into next year. Iron ore prices are normally set in annual talks between major suppliers and customers. As they have been unable to agree upon a benchmark price, iron ore is being sold on the open market. Prices spiked in early August, but we have seen a decline since then. The company's policy of strict fiscal discipline and cost control will help us weather these up and down prices we're now seeing, and allow us to be profitable as we move forward."
The full shareholder letter can be viewed on Jaguar Mining's website at www.jaguarminingenterprises.com.
FOUNTAIN HEALTHY AGING INCORPORATED (OTCBB: FHAI)
"Up 35.14% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FHAI.php
Fountain Healthy Aging is a company specifically focussed in the anti aging industry, which is one of the quickest growing industry sectors worldwide. We have a range of products targeted at the anti-aging market, including our revolutionary flagship product Vitalife, which we believe is ready to make a massive impact in the anti-aging industry. We recognize the importance of the anti-aging sector, an emerging dynamic within the overall health and wellness revolution. We believe that we are uniquely positioned to capitalize on this rapidly growing trend, first with our unique flagship product, rapidly followed by our other products which have been specifically developed for this market. Fountain Healthy Aging's main focus is on the specialty, premium product category, which is a growing segment of the market that provides gross margins significantly higher that the lower-priced, mainstream health products market.
FHAI News:
August 12 - Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured
Fountain Healthy Aging Inc. (OTCBB: FHAI) announced on August 12 2009 that it had entered into an agreement with Dunn Capital Partners and Oak Resources Limited which provides the Company with a $5,000,000 Equity Line of Credit investment. Under the terms of the agreement, Fountain has the right to draw down from the Equity Line Investment in tranches of up to $1,000,000 each, for a term of 24 months. The first tranche investment of $1,000,000 was drawn down by Fountain on August 10 2009.
Fountain CEO, Paul Hunston, said "We are very pleased to have secured this $5,000,000 equity line of credit, which will enable us to fully implement our business plan and accelerate the Company's growth both within the
Michael Bailey, head of Equity Capital markets at Dunn Capital Partners said: "We take pride in our ability to identify companies with strong management teams, growth potential and competitive advantages. We are delighted that through Oak Resources, we have been able to make this investment in Fountain. We think Fountain is perfectly positioned to leverage its high quality and natural product range and take advantage of its unique positioning in the market place. We look forward to working with Oak Resources and Fountain in helping the Company realize and execute its full growth potential."
ABOUT DUNN CAPITAL PARTNERS
Dunn Capital Partners is a private investment company and is focused on investing in growing Small Cap issuers with solid fundamentals.
Dunn Capital Partners typically invests anywhere from $10,000,000 to $250,000,000+ with companies seeking a long-term funding partner and a strategic partner to support its growth.
Dunn Capital Partners is committed to investing in companies with strong management who have the ability to execute their business plan upon the receipt of growth capital.
Dunn Capital Partners is industry and geography agnostic.
BIOELECTRONICS CORPORATION (OTC:
"Up 16.42% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BIEL.php
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx™ Devices, HealFast™ Therapy (www.healfasttherapy.com) and the Allay™ family of inexpensive, disposable drug-free anti-inflammatory devices.
September 8 - A New Audio Interview with Andrew Whelan, CEO of BioElectronics, Inc., is now at SmallCapVoice.com
SmallCapVoice.com, Inc. announced that a new audio interview with BioElectronics Corp. (OTC:
VERIFY SMART CORPORATION (OTCBB: VSMR)
"Up 15.63% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/VSMR.php
VerifySmart Corp. designed and developed a Proprietary Hardware/Software Solution that solves Credit/Debit Card fraud by using two Factor Authentication. The Company's Core Technology is designed to meet the needs of the Security challenged Trans action Processing Industry. Present day solutions, such as Verified by Visa, Chip and Pin and CVV Code (all which can be compromised) have not reduced payment card fraud by any significant factor. The VerifySmart solution has reduced fraud to zero in earlier production pilots. The Company's proven and highly scalable solution is gaining worldwide attention and placing VerifySmart at the forefront of the fraud prevention revolution.
VSMR News:
September 10 - VerifySmart™ Corp. targets Asia Pacific region; Initiates card fraud prevention dialogue with several of
VerifySmart™ Corp. (VSMR: OTCBB) ("VerifySmart" or the "Company"), a global leader in secure and fraud free payment credit and debit card processing services, announced that Mr. Adi Muljo, Senior Vice President of Business Development - Asia Pacific Region will initiate senior level discussions with representatives of several of the largest Banks serving the Asia Pacific region.
"The Asian Pacific Market represents a huge client opportunity for the VerifySmart™ Corporation and its portfolio of financial and technology service applications," says Mr. Muljo. "Our initial discussions have generated a lot of excitement as to the application and expansion of our technology. The need for security and payment authorization authentication in the expanding e-commerce market place cannot be overstated and this represents a significant opportunity for VerifySmart's credit and debit card transaction security technology."
E-commerce is growing at a rate exceeding 20 percent per year with some Asian markets growing as much as 40 percent annually. Amazon.com and eBay are among the most popular sites in
As ID theft and Credit/Debit card fraud surpassed $56 Billion annually, the need for secure payment authentication grows exponentially. VerifySmart™ technology adds a new layer of security to existing protocols, by notifying the cardholder of each and every purchase through the card holder's own cellular phone, thus enabling the cardholder to approve or decline his or her purchase via a secure PIN (personal identification number)
The resulting transaction represents to the merchant, to the underlying financial institution or credit provider, and to the card holder, an undisputed guarantee of acceptance. VerifySmart's new technology is a first in the industry and, if marketplace interest to date is any indication of the near-term need for a multi-billion dollar problem, then the Company should expect favourable response from potential partners.
"VerifySmart™ has the right product at the right time. We expect an impressive transaction growth rate, especially in this world of technology convergence," concludes Mr. Muljo. A new report from Portio Research predicts that half of the world's population currently have mobile devices, and further that over the next couple years, global penetration will reach 75 percent.
ABOUT MR. ADI MULJO
Mr. Muljo holds the strategic role of Senior Vice President of Business Development in the
Between 1971 and 1998, Mr. Muljo held various senior management positions with
From 1981-1998, Mr. Muljo was responsible for the Vancouver and Baltimore offices of the Astra Group and was also in charge of overseeing Astra's North American expansion directed from the Baltimore office, where Mr. Muljo makes his home.
Mr. Muljo holds a BA in Economics and an MBA in Finance. VSC management welcomes this significant appointment which we believe will accelerate the company's growth plan and enhance shareholder value. Mr. Muljo's past successes and extensive network in the Asia/Pacific Region is invaluable to the company's pursuit of becoming the premier provider of fraud prevention solutions across the globe.
DISCOVERY LABS INCORPORATED (NASDAQ: DSCO)
"Up 35.42% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/DSCO.php
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs is focused initially on developing its KL4 surfactant pipeline to build a pediatric franchise that will potentially address several respiratory conditions affecting neonates and young children, beginning with Respiratory Distress Syndrome (RDS).
DSCO News:
September 10 - Discovery Labs and FDA to Meet On September 29, 2009 to Discuss Potential Path for SURFAXIN Approval
Discovery Laboratories, Inc. (Nasdaq: DSCO) has received written notification from the U.S. Food and Drug Administration (FDA) that a meeting has been scheduled for September 29, 2009. This meeting will serve as a follow-up to the June 2 meeting with the FDA and the FDA's April 17 Complete Response letter. The objective of this meeting is to define the options available to Discovery Labs to resolve the remaining primary issue that Discovery Labs must address to gain
At the upcoming September 29 meeting, Discovery Labs plans to discuss with the FDA a limited Surfaxin clinical trial design and whether conducting such trial, while simultaneously employing the fetal rabbit Biological Activity Test (BAT, a quality control and stability release test), could potentially address the key remaining requirement for Surfaxin approval. This approach was suggested by the FDA at the June 2 meeting as a way for Discovery Labs to increase the likelihood of gaining Surfaxin approval. In addition, Discovery Labs plans to review its ongoing quality improvement efforts, intended to further refine the BAT in accordance with Discovery Labs' continuing quality improvement initiatives, with the FDA.
Background
The April 17 Complete Response letter from the FDA and the June 2 meeting focused primarily on certain aspects of the BAT, specifically whether preclinical data generated using both the BAT and a well-established preterm lamb model of RDS adequately supports the comparability of Surfaxin clinical drug product to the to-be-manufactured Surfaxin, and whether the BAT can adequately distinguish change in Surfaxin biological activity over time.
During the conduct of Phase 3 clinical trials for Surfaxin, Discovery Labs employed an array of quality control tests, but did not employ the BAT to evaluate biological activity of the Surfaxin clinical drug product. After completing the Phase 3 clinical trials, in accordance with discussions with the FDA, Discovery Labs validated and implemented the BAT as a recurring quality control test to confirm biological activity for Surfaxin release and stability testing. Based on agreements reached in meetings with the FDA in 2006 and 2008, Discovery Labs conducted a series of preclinical experiments to establish comparability between Surfaxin drug product used in Phase 3 clinical trials and the Surfaxin drug product intended to be manufactured for commercial use. Accordingly, Discovery Labs initiated a series of side-by-side studies employing both the preterm lamb model of RDS and the BAT and believes that the correlated results demonstrate comparability and support approval of Surfaxin.
At the June 2 meeting with the FDA, Discovery Labs presented data from the preterm lamb model and BAT studies, together with a comprehensive statistical evaluation of such data, intended to establish the comparability of clinical drug product to Surfaxin drug product to be manufactured for commercial use. The comprehensive statistical evaluation was a comparative regression analysis using an accepted FDA statistical method. Discovery Labs believes that the data and related statistical evaluation are highly supportive of the comparability of clinical drug product to commercial Surfaxin.
However, the FDA stated at the June 2 meeting, that data generated from the preterm lamb model and BAT studies must demonstrate, in a point-to-point analysis, the same relative changes in respiratory compliance between both models over time. Based on this standard, Discovery Labs believes that establishment of comparability in this manner would be an extremely high hurdle and that, from the FDA's perspective, the data analysis provided by Discovery Labs did not meet that standard.
In addition, the FDA suggested that the comparability studies in the preterm lamb model and the BAT would not be necessary if the BAT had been implemented to assess Surfaxin drug product used in the Phase 3 clinical trials. The FDA also suggested that, to increase the likelihood of gaining Surfaxin approval and as an alternative to demonstrating comparability using the preterm lamb model and BAT, Discovery Labs could consider conducting a limited clinical trial, while simultaneously employing the BAT, as a path forward to Surfaxin approval.
SPEEDUS CORPORATION (NASDAQ: SPDE)
"Up 24.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SPDE.php
Speedus Corp., through its subsidiaries, engages in healthcare, restaurant, and wireless businesses in the
SPDE News:
September 11 - Density Dynamics Develops Distribution; Signs International Rep Agreement
Density Dynamics, a majority owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced that it has signed an International Representation agreement covering
"We are excited to establish a sales and distribution channel for the cutting-edge DRAM-based SSD's built for high speed data enterprise users. My experience at Wachovia in the data center environment led me to witness the Jet.io SSD. Its power and performance capabilities are highly anticipated in the Indian market and together with Graphay's technologies, will address pressing needs of our
ABOUT DENSITY DYNAMICS
Density Dynamics, a majority owned subsidiary of Speedus Corp., is a pioneer in the solid-state storage and I/O acceleration technology. Its high performance RamFlash solid-state storage and computing devices are designed to reduce I/O bottlenecks while also reducing power, cooling, and rack space requirements.
ABOUT GRAPHAY
Graphay, headquartered in Matthews, NC, is an Enterprise IT Solutions Provider to customers in
VIA PHARMACEUTICALS INCORPORATED (NASDAQ: VIAP)
"Up 8.37% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/VIAP.php
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation.
VIAP News:
July 17 - VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced that it received a Staff Determination letter, dated July 15, 2009, from the NASDAQ Stock Market stating that the Company has not regained compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing, as set forth in Listing Rule 5550(b), and that the Company's securities are, therefore, subject to delisting from The NASDAQ Capital Market.
The Company intends to file an appeal of the NASDAQ Staff Determination by July 22, 2009 and to request a hearing before a NASDAQ Listing Qualifications Panel (the "Panel"), which request will stay the delisting of the Company's securities pending the Panel's decision. There can be no assurance that the Panel will grant the Company's request for continued listing on The NASDAQ Capital Market.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated three thousand five hundred dollars from a third party (Longview Communications Corp.) for ACCP advertising and promotional services. OTCPicks.com has been compensated nine thousand five hundred dollars by the company for CHYU advertising and promotional services. OTCPicks.com is being compensated eight thousand dollars by a third party (Mickey Reno) for EWRC advertising and promotional services. OTCPicks.com has been compensated two thousand five hundred dollars by a third party (BlueWave Advisors) for KNDR advertising and promotional services. OTCPicks.com has been compensated five thousand dollars by a third party for OGNG advertising and promotional services. OTCPicks.com has been compensated two hundred thousand free trading shares by a third party (Microcap Management) for JAGR advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
